HomeCompareGRBMF vs ABBV

GRBMF vs ABBV: Dividend Comparison 2026

GRBMF yields 1.43% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GRBMF wins by $5.69M in total portfolio value· pulled ahead in Year 5
10 years
GRBMF
GRBMF
● Live price
1.43%
Share price
$3.60
Annual div
$0.05
5Y div CAGR
92.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.79M
Annual income
$4,849,301.99
Full GRBMF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GRBMF vs ABBV

📍 GRBMF pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRBMFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRBMF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GRBMF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRBMF
Annual income on $10K today (after 15% tax)
$121.60/yr
After 10yr DRIP, annual income (after tax)
$4,121,906.69/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GRBMF beats the other by $4,100,850.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRBMF + ABBV for your $10,000?

GRBMF: 50%ABBV: 50%
100% ABBV50/50100% GRBMF
Portfolio after 10yr
$2.95M
Annual income
$2,437,036.88/yr
Blended yield
82.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GRBMF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
2.3
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRBMF buys
0
ABBV buys
0
No recent congressional trades found for GRBMF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRBMFABBV
Forward yield1.43%3.06%
Annual dividend / share$0.05$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR92.8%40.6%
Portfolio after 10y$5.79M$102.3K
Annual income after 10y$4,849,301.99$24,771.77
Total dividends collected$5.69M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: GRBMF vs ABBV ($10,000, DRIP)

YearGRBMF PortfolioGRBMF Income/yrABBV PortfolioABBV Income/yrGap
1$10,976$275.81$11,550$430.00$574.00ABBV
2$12,290$545.47$13,472$627.96$1.2KABBV
3$14,250$1,100.51$15,906$926.08$1.7KABBV
4$17,547$2,299.36$19,071$1,382.55$1.5KABBV
5← crossover$23,877$5,101.69$23,302$2,095.81+$575.00GRBMF
6$38,057$12,508.71$29,150$3,237.93+$8.9KGRBMF
7$76,646$35,924.46$37,536$5,121.41+$39.1KGRBMF
8$212,377$130,365.66$50,079$8,338.38+$162.3KGRBMF
9$878,129$650,885.67$69,753$14,065.80+$808.4KGRBMF
10$5,788,900$4,849,301.99$102,337$24,771.77+$5.69MGRBMF

GRBMF vs ABBV: Complete Analysis 2026

GRBMFStock

Grupo Bimbo, S.A.B. de C.V., together with its subsidiaries, produces, distributes, and sells various bakery products. The company offers sliced bread, buns and rolls, pastries, cakes, cookies, toast bread, English muffins, bagels, tortillas and flatbreads, salty snacks, and confectionery products. It provides its products under approximately 100 brands. The company operates 206 bakeries and other plants and approximately 1,600 sales centers in 33 countries, including Mexico, the United States, Canada, Latin America, Europe, Asia, and Africa. The company was founded in 1945 and is headquartered in Mexico City, Mexico with additional locations in Argentina, Brazil, Canada, Chile, China, Colombia, Costa Rica, Ecuador, El Salvador, France, Guatemala, Honduras, India, Italy, Kazakhstan, Mexico, Morocco, Nicaragua, Panama, Paraguay, Peru, Portugal, Russia, South Africa, South Korea, Spain, Switzerland, Turkey, Ukraine, the United Kingdom, Uruguay, the United States, and Venezuela.

Full GRBMF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GRBMF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRBMF vs SCHDGRBMF vs JEPIGRBMF vs OGRBMF vs KOGRBMF vs MAINGRBMF vs JNJGRBMF vs MRKGRBMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.